biostudies-literatureBond ACSNIAID NIH HHSNIGMS NIH HHS105817https://www.ebi.ac.uk/biostudies/studies/S-EPMC10922812biostudies-literatureUnknown222JC polyomavirus (JCPyV) is a nonenveloped, double-stranded DNA virus that infects the majority of the population. Immunocompetent individuals harbor infection in their kidneys, while severe immunosuppression can result in JCPyV spread to the brain, causing the neurodegenerative disease progressive multifocal leukoencephalopathy (PML). Due to a lack of approved therapies to treat JCPyV and PML, the disease results in rapid deterioration, and is often fatal. In order to identify potential antiviral treatments for JCPyV, a high-throughput, large-scale drug screen was performed using the National Institutes of Health Clinical Collection (NCC). Drugs from the NCC were tested for inhibitory effects on JCPyV infection, and drugs from various classes that reduced JCPyV infection were identified, iAntiviral researchHigh-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.PMC10922812R15 AI144686P20 GM103423P20 GM144265Leclerc NRWilczek MPBond ACSBennett LJMaginnis MSSandberg ALCrocker MADuShane JKfalseHigh-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.JC polyomavirus (JCPyV) is a nonenveloped, double-stranded DNA virus that infects the majority of the population. Immunocompetent individuals harbor infection in their kidneys, while severe immunosuppression can result in JCPyV spread to the brain, causing the neurodegenerative disease progressive multifocal leukoencephalopathy (PML). Due to a lack of approved therapies to treat JCPyV and PML, the disease results in rapid deterioration, and is often fatal. In order to identify potential antiviral treatments for JCPyV, a high-throughput, large-scale drug screen was performed using the National Institutes of Health Clinical Collection (NCC). Drugs from the NCC were tested for inhibitory effects on JCPyV infection, and drugs from various classes that reduced JCPyV infection were identified, i2024-01-01T00:00:00Z2024 Feb2025-04-05T10:19:28.406Z2025-04-05T10:19:28.406ZS-EPMC109228123824620710.1016/j.antiviral.2024.105817